NPCA Third Year Annual Report 2016
13.01.17 – The National Cancer Registration and Analysis Service (NCRAS) has notified the NPCA that the data extract provided to the NPCA Project Team for analysis and presentation in the 2016 Annual Report is incomplete for some Trusts. The NPCA informed all Trusts providing prostate cancer care about this issue and circulated an apology from Jem Rashbass, National Director for Disease Registration and Cancer Analysis.
02.02.17 – The NPCA Team published an erratum presenting the analysis carried out by the NPCA Project Team following receipt of the missing data from NCRAS. Data for an additional 1,093 men are included in the analysis, which is presented in updated Tables 2.1, 2.2 and Appendix 2 from the 2016 Annual Report.
22.06.17 – Following Trust feedback the NPCA team have worked with the NCRAS to determine the best way to allocate patients to the Trust where their prostate cancer was diagnosed. These investigations have been summarised in a ‘Lessons Learnt’ document. An Updated Erratum presenting Tables 2.1, 2.2 and Appendix 1 using this new approach was published, in addition to the algorithm developed by NCRAS to determine ‘Trust of diagnosis’
The third Annual Report of the National Prostate Cancer Audit was published on the 14th December 2016 and presents current data regarding prostate cancer care in England and, for the first time, in Wales. In this report, the NPCA has taken things further by gathering information directly from patients to find out their views of their experience of care and the functional impact of radical treatments on their lives.
This Annual Report presents results of the first year of the prospective audit for men diagnosed with prostate cancer between 1st April 2014 and 31st March 2015 in England. Results of the prospective audit in Wales, where NPCA data collection started one year later, for men diagnosed between 1st April 2015 – 31st September 2015 are also presented. Patient-reported outcomes and experience measures (PROMs and PREMs) following radical local treatment of prostate cancer were collected using a survey distributed to individual patients in England 18 months after diagnosis and subsequent treatment. These results, representing one of the largest individual patient treatment surveys undertaken in the UK, are presented for the first time in this Annual Report. They will provide valuable information enabling clinicians to assess the overall effects of treatment and health care providers to study and understand variation in practice and outcomes in different geographical areas.
The report is primarily written for clinicians, providers of prostate cancer services, commissioners and health care regulators. A version presenting the results to patients and the wider public is being produced separately and will be available in Spring 2017.
The report and executive summary are available to download using the links below